Retractable Q3 net sales $10.1M, operating loss $3.7M; receives Vizient designation

RETRACTABLE TECHNOLOGIES INC

2025-Q3 EPS reported -$0.35 revenue$28,826,629

Q3 net sales $10.1M (down from $10.3M YoY); operating loss $3.7M vs $5.1M loss last year.
Net income $371k in Q3 includes $2.4M unrealized gains on securities; 9-month net loss $10.2M.
Tariffs on needles from China at 130%; $2.3M spent on tariffs in first nine months of 2025.
U.S. manufacturing share rose to 38.3% in 2025 from 10% in 2024; workforce reductions implemented.
EasyPoint Blood Collection Tube Holder with Needle received Vizient Innovative Technology designation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.